GLP-1 Market
LLY $1288.30 ▲ +0.5% NVO $38.29 ▼ -1.0% PFE $29.45 ▼ -1.2% VKTX $25.36 ▲ +1.9% KLRA $13.42 ▲ +2.2% GPCR $21.48 ▼ -0.3% RHHBY $60.22 ▼ -0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Leriglitazone

Company
Minoryx Therapeutics, S.L.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 29, 2026

Trial details
  • Completed NCT NCT03231878

    A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients

    Not yet reported, Not yet reported Minoryx Therapeutics, S.L. 116 participants Est. completion 2025-03-06 10 sites
    Other conditions: Adrenoleukodystrophy
    View official trial listing →
  • Completed NCT NCT03917225

    A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients

    Not yet reported Minoryx Therapeutics, S.L. 39 participants Est. completion 2020-09-14 5 sites Stand-alone
    Other conditions: Friedreich Ataxia
    View official trial listing →
  • Status unknown NCT NCT04528706

    A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

    Not yet reported Minoryx Therapeutics, S.L. 13 participants Est. completion 2023-12-31 5 sites Stand-alone
    Other conditions: Cerebral Adrenoleukodystrophy
    View official trial listing →
  • Active, not recruiting NCT NCT05819866

    A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

    Not yet reported Minoryx Therapeutics, S.L. 40 participants Est. completion 2027-05 11 sites
    Other conditions: Cerebral Adrenoleukodystrophy (cALD)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Leriglitazone, MIN-102

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.